IBS Treatment Market 2018 - Major Participants: Allergan Plc, Sucampo Pharmaceuticals, Ironwood Pharmaceuticals, Inc., Astellas Pharma Inc., Valeant Pharmaceuticals, Abbott Laboratories, Synergy Pharmaceuticals,

The, IBS Treatment Market inquire about report is developing with the quick pace; chiefly due the prospering Healthcare Sector. As per a current report distributed by the Market Research Future, The , IBS Treatment Industry Research report is blasting and anticipated that would pick up unmistakable quality over the conjecture time frame. The Market is anticipated to exhibit a colossal development by 2023, outperforming its past development records as far as esteem and volume.

TRY FREE SAMPLE REPORT @ https://www.marketresearchfuture.com/sample_request/5555 .

The Americas IBS treatment market is expected to grow at a CAGR of 9.3% during the forecast period 2017-2023.

Market Scenario:

Irritable bowel syndrome (IBS) is a common disorder that affects the digestive system. IBS is characterized by symptoms such as stomach cramps, bloating, diarrhea, and constipation, which impacts one’s everyday life. Although the cause of IBS is unknown, but few factors that cause IBS are severe infection, inflammation in the intestines, muscle contractions in the intestine, changes in bacteria in the gut, and abnormalities in the nerves. Rising prevalence of gastrointestinal diseases and disorder, geriatric population, unhealthy diet, anxiety, depression, and changing lifestyle in Americas are the key drivers of the Americas IBS market. Moreover, strong clinical pipeline and government support is fuelling the market in this region. According to an updated report by the Anxiety and Depression Association of America, in 2017, the most common mental disorder was anxiety in the United States, affecting approximately 40 million adults over 18 years every year. Additionally, According to a report of the National Institute of Mental Health, in 2015, approximately 16.1 adults over 18 years in the United States had at least one major depressive episode in the past one year, which is 6.7% of all the U.S. adults. These number generate the huge demand for better treatment in this region.

Hence, most of the companies are more into mergers, acquisition, and collaboration activity in order to provide better treatment procedure. In this regards, Allergan Plc. in January 2017, entered into a licensing agreement with Assembly Biosciences, Inc. for worldwide rights to Assembly's micro biome GI development programs. Also, in October 2016, Allergan Plc. announced the formation of the IBS CounSEL, group of experts dedicated to improve diagnosis and management of irritable bowel syndrome (IBS) by providing support. These merger and acquisition help the companies to introduce quality treatment and expand the product line within the region. Companies are also focusing on research and development activities to get better approach to treat IBS. In this regards, in September 2017, Sucampo Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) have accepted the application of supplemental new drug application (sNDA) for lubiprostone (AMITIZA) in children.

Furthermore, increasing consumer awareness about the irritable bowel syndrome increase the footfall of patient in clinics and hospitals. Furthermore, increasing spending in the healthcare domain fuelling the growth of the IBS treatment market. According to the Centers for Medicare & Medicaid Services, in 2015, the U.S. healthcare spending increased by 5.8% reaching USD 3.2 trillion. In 2016, the healthcare spending in North America had increased to some extent.

However, strict FDA regulations and unsatisfactory effectiveness of the treatment may hinder the growth of Americas IBS treatment market during forecast period.

Key Players:

Some of the key players in this market are Allergan Plc (Ireland), Sucampo Pharmaceuticals (U.S.), Ironwood Pharmaceuticals, Inc. (U.S.), Astellas Pharma Inc. (Japan), Valeant Pharmaceuticals (Canada), Abbott Laboratories (U.S.), Synergy Pharmaceuticals, Inc. (U.S.), Ardelyx, Inc. (U.S.), Nestle (Switzerland), Sebela Pharmaceuticals (Ireland), Probi (Sweden), Alfasigma USA, Inc. (Italy), RedHill Biopharma Ltd. (Israel), AstraZeneca (U.K), Ipsen (France), Novartis AG (Switzerland), Takeda Pharmaceutical Company Ltd (Japan), Synthetic Biologics, Inc. (U.S.), Protagonist Therapeutics Inc. (U.S.), Pfizer Inc (U.S.), Lexicon Pharmaceuticals, Inc. (U.S.), Innovate Biopharmaceuticals (U.S.), 4D pharma plc (U.K).

Regional Analysis:

The Americas region is divided into North America and South America. North America command the largest market of IBS treatment owing to the well presence of health care structure, government support, various research and development programs, increasing sensitivity and specificity for diagnosing IBS, aware and concerned individual, and presence of well-developed clinical laboratories. Moreover, presence of strong economic condition, and focus of research institutions on updating technology for new and advanced IBS treatment fuel the growth of market in this region. Also, the countries in this region have multiple companies which are involved in the IBS treatment business. North America is further divided into the U.S. and Canada. Both of these countries have good economic growth and great standard of living. According to a report published by the International Foundation for Functional Gastrointestinal Disorders, in 2016, functional gastrointestinal (GI) and motility disorders are the most common GI disorders which accounted for 1 in 4 people or more in the United States.

Segmentation:

The Americas IBS treatment market is segmented on the basis of types, drugs type, and end user.

On the basis the types, it is segmented into IBS-D, IBS-C, IBS-M.

On the basis of the drugs type, it is segmented into lubiprostone, linaclotide, eluxadoline, rifaximin, alosetron, and others.

On the basis of the end users, it is segmented into hospitals, clinics, and research laboratories.

AVAIL AMAZING DISCOUNT ON REPPRT @ https://www.marketresearchfuture.com/check-discount/5555 .

Key Findings:

The Americas IBS treatment market is estimated at USD 1,959.5 million in 2016.
IBS-C is the fastest growing segment, which is projected grow at a CAGR of 9.6% during the forecast period 2017-2023.
Linaclotide is the fastest growing drugs type segment, which is expected to USD 1,164.8 million by 2023.
The United States captured the largest market of Americas and is expected to USD 2,660.9 million by 2023.
MAJOR TABLE OF CONTENTS:

1 REPORT PROLOGUE
2 MARKET INTRODUCTION
2.1 Scope Of Study 11
2.2 Research Objective 11
2.3 Assumptions & Limitations 11
2.3.1 Assumptions 11
2.3.2 Limitations 11
2.4 Market Structure 12

3 RESEARCH METHODOLOGY
3.1.1 Primary Research Methodology 14
3.1.2 Data Points Received From The Doctors/ Gastrologist: 14
3.1.3 Data Points Received From The Manufacturer/ Pharmaceutical Companies: 15
3.1.4 Data Points Received From Hospitals, Clinics: 15
3.1.5 Secondary Research Methodology 17
3.1.6 Market Share Analysis 19
3.1.7 Trade Analysis 19
3.1.8 Market Pricing Approach 19

4 MARKET DYNAMICS
4.1 Introduction 20
4.2 Drivers 21
4.2.1 Increasing Prevalence Of Anxiety (Impact Weightage: 37%) 21
4.2.2 Strong Clinical Pipeline (Impact Weightage: 35%) 22
4.2.3 Increasing Prevalence Of Depression (Impact Weightage: 28%) 23
4.3 Restraints 24
4.3.1 Strict FDA Regulations (Impact Weightage: 60%) 24
4.3.2 Unsatisfactory Effectiveness Of The Treatment (Impact Weightage: 40%) 25
4.4 Opportunity 26
4.5 Mega Trends 27
4.6 Macroeconomic Indicators 28

5 MARKET FACTOR ANALYSIS
5.1 Value Chain Analysis 29
5.1.1 Research And Development 29
5.1.2 Manufacturing 30
5.1.3 Distribution & Sales 30
5.1.4 Post-Sales Monitoring 30
5.2 Porters Five Forces 31
5.2.1 Threat Of New Entrants (Medium To High) 32
5.2.2 Bargaining Power Of Suppliers (Medium) 32
5.2.3 Threat Of Substitutes (Medium To High) 32
5.2.4 Bargaining Power Of Buyers (Medium) 32
5.2.5 Intensity Of Rivalry (Medium To High) 32
5.3 Demand & Supply: Gap Analysis 33
5.4 Pricing Analysis 33
5.5 Investment Opportunity Analysis 33
5.6 Merger And Acquisition Landscape 34

…CONTINUED

ASK ANY QUESTION @ https://www.marketresearchfuture.com/enquiry/5555 .

About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

Contact:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Maharashtra, India
+1 646 845 9312
Email: salesteam@marketresearchfuture.com

This release was published on openPR.